Alberto Picca
Overview
Explore the profile of Alberto Picca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abbar B, Labreche K, Cadranel J, Veyri M, Morin V, Thiam F, et al.
J Thorac Oncol
. 2025 Feb;
PMID: 39923848
Introduction: NSCLC is frequent and associated with poor prognosis among people living with human immunodeficiency virus (PLWHIV); nevertheless, the contributing factors remain unknown. Methods: We prospectively compared the immunogenomic characteristics...
2.
Silveira A, Houy A, Ganier O, Ozemek B, Vanhuele S, Vincent-Salomon A, et al.
Nat Commun
. 2024 Nov;
15(1):9864.
PMID: 39543136
Transition of cytosine to thymine in CpG dinucleotides is the most frequent type of mutation in cancer. This increased mutability is commonly attributed to the spontaneous deamination of 5-methylcytosine (5mC),...
3.
Baron M, Labreche K, Veyri M, Desire N, Bouzidi A, Seck-Thiam F, et al.
Haematologica
. 2024 Jun;
109(11):3615-3630.
PMID: 38841782
Non-Hodgkin lymphomas (NHL) commonly occur in immunodeficient patients, both those infected by human immunodeficiency virus (HIV) and those who have been transplanted, and are often driven by Epstein-Barr virus (EBV)...
4.
Picca A, Di Stefano A, Savatovsky J, Ducray F, Chinot O, Moyal E, et al.
Neurooncol Adv
. 2024 May;
6(1):vdae068.
PMID: 38813112
Background: Oncogenic FGFR-TACC fusions are present in 3-5% of high-grade gliomas (HGGs). Fexagratinib (AZD4547) is an oral FGFR1-3 inhibitor with preclinical activity in FGFR-TACC+ gliomas. We tested its safety and...
5.
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, et al.
Eur J Cancer
. 2024 Mar;
202:114034.
PMID: 38537315
Background: Novel effective treatments are needed for recurrent IDH mutant high-grade gliomas (IDHm HGGs). The aim of the multicentric, single-arm, phase II REVOLUMAB trial (NCT03925246) was to assess the efficacy...
6.
Picca A, Sansone G, Santonocito O, Mazzanti C, Sanson M, Di Stefano A
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067258
In 2012, whole-transcriptome sequencing analysis led to the discovery of recurrent fusions involving the and genes as the main oncological driver in a subset of human glioblastomas. Since then, fusions...
7.
Auffret L, Ajlil Y, Tauziede-Espariat A, Kergrohen T, Puiseux C, Riffaud L, et al.
Acta Neuropathol
. 2023 Dec;
147(1):2.
PMID: 38066305
Diffuse midline gliomas (DMG) H3 K27-altered are incurable grade 4 gliomas and represent a major challenge in neuro-oncology. This tumour type is now classified in four subtypes by the 2021...
8.
Picca A, Bruno F, Nichelli L, Sanson M, Ruda R
Expert Rev Neurother
. 2023 Nov;
23(12):1217-1231.
PMID: 37982735
Introduction: Lower-grade (grade 2-3) gliomas (LGGs) constitutes a group of primary brain tumors with variable clinical behaviors and treatment responses. Recent advancements in molecular biology have redefined their classification, and...
9.
Roberts H, Ji S, Picca A, Sanson M, Garcia M, Snuderl M, et al.
Acta Neuropathol
. 2023 Oct;
146(6):849-852.
PMID: 37851269
No abstract available.
10.
Farina A, Birzu C, Elsensohn M, Picca A, Muniz-Castrillo S, Vogrig A, et al.
Brain Commun
. 2023 Jun;
5(3):fcad169.
PMID: 37389303
While the spectrum of neurological immune checkpoint inhibitor-related adverse events is expanding, patients' outcomes are not well documented. This study aimed to assess outcomes of neurological immune-related adverse events and...